{"Neutralizing": [0], "antibodies": [1, 25, 47, 80, 97, 123], "elicited": [2, 95], "by": [3, 127], "prior": [4], "infection": [5], "or": [6, 81], "vaccination": [7], "are": [8, 26, 98], "likely": [9], "to": [10, 39, 44, 78], "be": [11, 85, 125], "key": [12], "for": [13], "future": [14], "protection": [15], "of": [16, 111, 121, 130], "individuals": [17], "and": [18, 32, 72], "populations": [19], "against": [20], "SARS-CoV-2.": [21], "Moreover,": [22], "passively": [23], "administered": [24], "among": [27], "the": [28, 37, 68, 109, 118, 128], "most": [29], "promising": [30], "therapeutic": [31, 119], "prophylactic": [33], "anti-SARS-CoV-2": [34], "agents.": [35], "However,": [36], "degree": [38], "which": [40], "SARS-CoV-2": [41, 61, 89, 106, 113], "will": [42], "adapt": [43], "evade": [45], "neutralizing": [46, 96, 136], "is": [48], "unclear.": [49], "Using": [50], "a": [51], "recombinant": [52], "chimeric": [53], "VSV/SARS-CoV-2": [54], "reporter": [55], "virus,": [56], "we": [57], "show": [58], "that": [59, 75, 92, 115, 133], "functional": [60], "S": [62, 90], "protein": [63], "variants": [64, 91, 114], "with": [65], "mutations": [66], "in": [67, 104], "receptor-binding": [69], "domain": [70, 74], "(RBD)": [71], "N-terminal": [73], "confer": [76], "resistance": [77], "monoclonal": [79, 122], "convalescent": [82], "plasma": [83], "can": [84, 124], "readily": [86], "selected.": [87], "Notably,": [88], "resist": [93], "commonly": [94], "now": [99], "present": [100], "at": [101], "low": [102], "frequencies": [103], "circulating": [105], "populations.": [107], "Finally,": [108], "emergence": [110], "antibody-resistant": [112], "might": [116], "limit": [117], "usefulness": [120], "mitigated": [126], "use": [129], "antibody": [131], "combinations": [132], "target": [134], "distinct": [135], "epitopes.": [137]}